CDMO Due Diligence: What to Review Before Selecting a Partner

CDMO due diligence is the process of evaluating a potential contract development and manufacturing partner before selection or engagement.

Depending on the stage of the sourcing process, diligence may include technical, operational, quality, regulatory, commercial, legal, and financial review.

Early-stage sourcing does not usually involve the same depth of diligence as formal vendor qualification.

The goal at the beginning is more practical:

Gather enough relevant information to determine whether the manufacturer is worth advancing.

PCN refers to this stage as preliminary diligence.

It helps sponsors investigate potential partners before deeper qualification, audits, contracting, and confidential technical discussions take place.

This distinction matters.

PCN can help sponsors review available information about project fit, facilities, capabilities, equipment, and regulatory context.

Formal CDMO selection may eventually require quality review, audits, technical assessments, legal review, quality agreements, supply agreements, validation work, financial diligence, and other sponsor-specific processes.

Preliminary diligence sits earlier in the funnel.

Its purpose is to help answer:

"Is there enough evidence here to justify the next conversation?"

Before digging into regulatory history or commercial details, confirm that the manufacturer appears capable of supporting the program technically.

That starts with the same requirements used to build the shortlist.

Review the modality, development stage, required capabilities, manufacturing scale, regulatory expectations, support needs, and other project-specific requirements.

A famous CDMO that cannot support the technical needs of the program is not a strong candidate simply because the company has a good reputation.

Diligence should begin with fit.

CDMO diligence becomes more useful when it moves below the parent-company level.

A company may operate several manufacturing sites, each with different technologies, equipment, scales, regulatory histories, and areas of specialization.

So the diligence target is often not just:

Company X

It is:

Company X, Facility Y, for this specific program

Where available, PCN incorporates facility-level information to help sponsors understand which manufacturing site may actually support the project.

This creates a more precise starting point for additional technical and quality diligence.

Broad claims such as "biologics CDMO" or "small molecule manufacturing" are useful for discovery, but diligence requires more detail.

Review the specific manufacturing capabilities that matter to the program.

Depending on the project, that may include process development, formulation, analytical capabilities, GMP manufacturing, fill finish, technology transfer, scale-up, drug substance, drug product, or other specialized services.

The important question is not how many capabilities appear on a company profile.

It is whether the required capabilities appear to exist at the relevant facility and scale for the project.

Equipment can materially affect manufacturing fit.

A facility may support the general modality but lack the specific equipment, production configuration, or scale required for the sponsor's process.

When structured information is available, reviewing manufacturing equipment can help teams identify questions to raise before entering more detailed discussions.

Production scale matters for the same reason.

A facility optimized for one scale may not be practical for another, even when the technical capability sounds similar on paper.

Equipment and scale should therefore be considered alongside the broader capability profile.

Regulatory history is an important part of CDMO due diligence, but it requires interpretation.

PCN provides access to FDA Form 483 information so sponsors can bring facility-level regulatory context into the sourcing process.

A Form FDA 483 should not be treated as an automatic pass or fail.

The useful diligence questions are more specific:

What observations were made?

Which facility was involved?

How relevant are those observations to the work being considered?

What happened afterward?

Are there subsequent actions or responses that should be reviewed?

How does the regulatory context compare with the technical and operational case for the facility?

The objective is not to produce a simplistic compliance score.

It is to surface information that may deserve additional attention during formal quality and regulatory diligence.

The type of manufacturer a sponsor needs can change as the program develops.

A preclinical or Phase I team may prioritize flexibility, development support, smaller-scale manufacturing, and close technical collaboration.

A later-stage or commercial program may place more emphasis on larger-scale operations, supply reliability, process robustness, validation, and commercial readiness.

When comparing CDMOs, consider whether the manufacturer's operating model appears appropriate for the current stage of the program.

A technically capable CDMO may still be a poor operational fit if its typical projects, scales, or client model do not align with the sponsor.

A technically excellent manufacturing partner is not useful if it cannot support the program when the sponsor needs it.

Timing should therefore be investigated early.

Sponsors should eventually verify project kickoff, scheduling, manufacturing slots, development timelines, and other availability details directly with the CDMO.

Do not assume that a listed capability means capacity is immediately available.

PCN can help identify potentially relevant partners, but actual project timing should be confirmed with the manufacturer.

Geography may be a preference for one sponsor and a major operational requirement for another.

Consider factors such as proximity to the sponsor team, supply-chain logistics, regulatory markets, technology-transfer needs, travel requirements, and internal preferences.

Geography should not automatically eliminate a technically suitable partner unless location is truly important to the program.

The point of diligence is to understand why a criterion matters before using it to narrow the shortlist.

Some sponsors need a manufacturing vendor.

Others need a development partner.

Those are not necessarily the same thing.

Early-stage teams may need significant support with process development, analytical work, formulation, scale-up, technology transfer, or project planning.

More mature programs may come to the CDMO with a well-defined process and a narrower manufacturing scope.

Before choosing a partner, determine how much technical and operational support the sponsor expects from the CDMO.

This can materially affect which manufacturer is the better fit.

One of the most useful outputs of preliminary diligence is a list of unanswered questions.

A sponsor does not need every answer before speaking with a CDMO.

It does need to know what still requires confirmation.

A practical diligence view might look like this:

The point is not to pretend uncertainty does not exist.

The point is to manage it deliberately.

Once a manufacturer has passed preliminary diligence, the next conversation should test the assumptions that put it on the shortlist.

Useful questions depend on the program, but the sponsor should generally be trying to confirm technical fit, relevant facility, project scope, scale, timing, support model, regulatory expectations, and any unresolved diligence issues.

The discussion should move beyond:

"Do you offer this service?"

and toward:

"How would your organization actually support this program?"

That is a much more useful sourcing conversation.

FDA 483 information can provide useful context about a manufacturing facility, but it should be interpreted carefully.

The existence of a Form 483 does not, by itself, tell a sponsor whether a CDMO should or should not be selected.

Sponsors should consider the observations, facility, timing, subsequent history, technical relevance, and the sponsor's own quality expectations.

PCN brings FDA 483 information closer to the sourcing workflow so teams can identify regulatory questions earlier rather than discovering them late in the selection process.

Formal regulatory and quality review still belongs to the sponsor and its qualified advisors.

The goal of preliminary diligence is not to eliminate every possible risk before speaking with a manufacturer.

It is to decide which conversations are worth having.

A structured sourcing process can therefore move through:

1. Define→
2. Match→
3. Compare→
4. Diligence→
5. Connect

By the time a sponsor requests an introduction, it should have a clearer reason for why that manufacturer is being considered and a better understanding of what still needs to be verified.

PCN allows sponsors to reuse structured project information when requesting an introduction, giving the CDMO context about the opportunity before deciding whether to proceed.

The manufacturer can then confirm interest and indicate whether the project may fit.

Pharma Connect Navigator is designed to bring early CDMO search, comparison, preliminary diligence, and sponsor-CDMO connection into one workflow.

Sponsors can start with the requirements of their manufacturing program, identify potential matches, and investigate available information about the company and facility before beginning outreach.

Depending on the available profile information, that may include project fit, manufacturing capabilities, facilities, equipment, regulatory context, and FDA Form 483 information.

It helps sponsors make the early sourcing process more structured and identify which manufacturing partners may deserve deeper review.